Navigation Links
OncoGenex Pharmaceuticals CEO Named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R) in the Health Sciences Category
Date:10/9/2009

BOTHELL, WA, and VANCOUVER, Oct. 9 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that Scott Cormack, president and chief executive officer of OncoGenex, has been named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R). The Ernst & Young Entrepreneur Of The Year(R) Award is a high profile business award recognizing entrepreneurs that are building successful, dynamic businesses.

"I share this award with our co-founder Dr. Martin Gleave and all of our employees at OncoGenex, whose contributions and exceptional dedication to our programs have led to a series of major clinical and business advancements over the past 12 months," said Scott Cormack, President and CEO of OncoGenex.

"Over the past year, we have presented impressive data from the clinical trials of our lead drug candidate, OGX-011, for the treatment of advanced prostate cancer; reached agreements with the FDA on the design of two Phase 3 trials for evaluating OGX-011 treatment in advanced prostate cancer via the FDA's special protocol assessment process; received Fast Track designations from FDA for OGX-011 in combination with both first-line and second-line chemotherapy in advanced prostate cancer, which are expected to streamline the regulatory review process; presented data from our Phase 1 clinical trial evaluating our second product candidate, OGX-427; and initiated another clinical trial with OGX-427 in bladder cancer," Cormack said.

"For the remaining 2009 year, we are committed to securing a partner to support the final stage of development of OGX-011 and announcing additional development initiatives for our other product candidates."

Ernst & Young's Entrepreneur Of The Year(R) Award encourages entrepreneurial activity among those with potential and recognizes the contribution
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 Quincy Bioscience, a leading ... of calcium-binding proteins to support healthy living, is ... study of apoaequorin in Food and ... the British Industrial Biological Research Association. , ... potential adverse effects, if any, of apoaequorin, in ...
(Date:5/23/2013)... Colo. , May 23, 2013 Venaxis, ... diagnostic company focused on obtaining FDA clearance and commercializing ... today announced the pricing of an underwritten public offering ... warrants to purchase 3,500,000 shares of its common stock ... a combined public offering price of $1.25 per share ...
(Date:5/23/2013)... May 23, 2013 Graphite Metallizing ... self-lubricating bushings mounted in stainless steel pillow blocks. ... of GRAPHALLOY with the application and installation versatility ... Pillow Blocks work exceptionally well when submerged ... hostile liquids such as acids, alkalies, hydrocarbons, black ...
(Date:5/23/2013)... 23, 2013  Rahal Letterman Lanigan Racing (RLL) and ... stem cell banking and therapeutics, announced today that StemCyte ... Acorn Stairlifts Indy car driven by James ... the IZOD IndyCar 2013 season.   StemCyte, ... support awareness of umbilical cord blood banking and its ...
Breaking Biology Technology:Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3
... , , , ... CRGN ) today reported its financial results for the ... its outstanding convertible debt and reached an agreement in principle, expressed ... lawsuits filed in the State of Connecticut and the State of ...
... PHILADELPHIA, July 30 eResearchTechnology, Inc. (ERT), (Nasdaq: ERES ), ... biopharmaceutical, medical device and related industries, announced today results for the second ... all comparative numbers refer to changes from the same period a year ... of the second quarter of 2009 were: , , ...
... , , , ... Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: ... 2009, the Company entered into definitive purchase agreements with certain ... including Cato Holding Company, which is the venture capital affiliate ...
Cached Biology Technology:CuraGen Reports Second Quarter 2009 Financial Results 2CuraGen Reports Second Quarter 2009 Financial Results 3CuraGen Reports Second Quarter 2009 Financial Results 4CuraGen Reports Second Quarter 2009 Financial Results 5CuraGen Reports Second Quarter 2009 Financial Results 6CuraGen Reports Second Quarter 2009 Financial Results 7CuraGen Reports Second Quarter 2009 Financial Results 8ERT Reports Second Quarter 2009 Results 2ERT Reports Second Quarter 2009 Results 3ERT Reports Second Quarter 2009 Results 4ERT Reports Second Quarter 2009 Results 5ERT Reports Second Quarter 2009 Results 6ERT Reports Second Quarter 2009 Results 7ERT Reports Second Quarter 2009 Results 8ERT Reports Second Quarter 2009 Results 9ERT Reports Second Quarter 2009 Results 10ERT Reports Second Quarter 2009 Results 11ERT Reports Second Quarter 2009 Results 12Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing 2Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing 3Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing 4Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing 5
(Date:5/22/2013)... durability in fuel cell powered buses, including a ... between electrode degradation processes and bus membrane durability. ... electrode degradation stressors in the operating cycle of ... findings of the study, led by SFU graduate ... long-term study at Burnaby-based Ballard Power Systems and ...
(Date:5/22/2013)... in a major new effort to educate the public ... people with clean water that looms ahead in the ... in the current edition of Chemical & Engineering ... Society (ACS), the world,s largest scientific society. , Bassam ... L. Schnoor, Ph.D., explain that shortages of reliable supplies ...
(Date:5/22/2013)... to genetic engineering drastically reduces the time and ... the workhorses of biotechnology, scientists are reporting. Published ... the method paves the way for more rapid ... cleanup and other activities. , Keith Shearwin and ... of the genetic material DNA into a bacterium,s ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2
... -- By creating a unique system of blood vessels ... an implanted device, the longevity and function of these ... led by researchers in the University of Louisville/ Jewish ... early online on August 23, 2010 in the ...
... a single gene can cause several types of developmental ... With support from the National Institutes of Health, ... a new gene scanning technology that cuts the cost ... is going to change the way we approach single-gene ...
... Iowa State University researchers will use grants of ... molecules, test technology that can detect food contamination, design ... with potential to grow the state,s economy. The ... to award 10 competitive grants totaling $942,389 from Iowa ...
Cached Biology News:New technology may prolong the life of implanted devices, from pacemakers to chemotherapy ports 2Gene scan finds link across array of childhood brain disorders 2Gene scan finds link across array of childhood brain disorders 3Iowa State awards grants to develop health, energy and research technologies 2Iowa State awards grants to develop health, energy and research technologies 3Iowa State awards grants to develop health, energy and research technologies 4
...
...
... >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long been ... radiolabeled ligands selected to keep pace with ... of products and services for receptor research ... radioligands. If you do not find exactly ...
... developed using a protein engineering approach that introduced ... of wild-type DNase I. These changes markedly increase ... result is a versatile enzyme that has a ... to maintain at least 50% of peak activity ...
Biology Products: